BMRN Stock Analysis: Biomarin Pharmaceutical | NASDAQ

Enzyme Therapies, Rare Diseases, Metabolic Treatments, Growth Disorders

Total Rating 50

Safety 66

Buy Signal 0.19

Biotechnology
Industry Rotation: -7.3

Market Cap: 13.6B
Avg Turnover: 130M

Risk 3d forecast

Volatility32.3%

VaR 5^th Pctl5.17%

VaR vs Median-2.55%

Reward TTM

Sharpe Ratio0.48

Rel. Str. IBD73.2

Rel. Str. Peer Group45.8

Character TTM

Beta0.303

Beta Downside0.453

Hurst Exponent0.431

Drawdowns 3y

Max DD49.83%

CAGR/Max DD-0.18

CAGR/Mean DD-0.31

EPS (Earnings per Share)

EPS CAGR: 23.72%
EPS Trend: 63.6%

Last SUE: 0.40
Qual. Beats: 0

Revenue

Rev. CAGR: 15.02%
Rev. Trend: 99.1%

Last SUE: 2.45
Qual. Beats: 1

Warnings

P/E Ratio 189.8

Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan -1.8% 20

Feb -0.4% 7

Mar -2.9% 54

Apr -1.8% 11

May -0.5% 10

Jun +2.5% 16

Jul +1.4% 23

Aug +1.7% 20

Sep -5.3% 65

Oct -4.8% 42

Nov +5.0% 70

Dec +1.2% 37

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: BMRN Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. (BMRN) is a U.S.-based biotechnology company founded in 1996 and headquartered in San Rafael, California, that develops and commercializes therapies for life-threatening rare diseases and medical conditions. It markets several specialty treatments, including VIMIZIM (MPS IV type A), VOXZOGO (achondroplasia), NAGLAZYME (MPS VI), PALYNZIQ (phenylketonuria), BRINEURA (Batten disease), ALDURAZYME, and KUVAN. Its pipeline includes BMN 333 for growth disorders and BMN 351 for Duchenne muscular dystrophy. The company sells globally-across the U.S., Europe, Latin America, the Middle East, and Asia Pacific-through specialty pharmacies, hospitals, government agencies, distributors, and pharmaceutical wholesalers, and holds a license and collaboration agreement with Ares Trading S.A.

As a large-cap biotechnology company listed on NASDAQ since 1999, BioMarin operates within the orphan drug business model, focusing on treatments for small patient populations with limited therapeutic alternatives. This specialization typically allows for extended market exclusivity under orphan drug designations, though it also concentrates revenue among a small number of high-cost specialty therapies.

Headlines to Watch Out For

VOXZOGO drives top-line growth as achondroplasia launch expands globally
PALYNZIQ revenue climbs with broader PKU patient uptake and label expansion
Pipeline catalysts from BMN 333 and BMN 351 shape long-term growth narrative

Piotroski VR-10 (Strict) 2.5

Net Income: 73.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -3.02 > 1.0
NWC/Revenue: 67.74% < 20% (prev 101.9%; Δ -34.14% < -1%)
CFO/TA 0.07 > 3% & CFO 857.1m > Net Income 73.0m
Net Debt (3.34b) to EBITDA (385.7m): 8.67 < 3
Current Ratio: 2.39 > 1.5 & < 3
Outstanding Shares: last quarter (194.1m) vs 12m ago -1.27% < -2%
Gross Margin: 75.55% > 18% (prev 79.56%; Δ -4.01% > 0.5%)
Asset Turnover: 35.52% > 50% (prev 41.09%; Δ -5.56% > 0%)
Interest Coverage Ratio: 2.78 > 6 (EBIT TTM 232.7m / Interest Expense TTM 83.6m)

Altman Z'' 2.77

A: 0.20 (Total Current Assets 3.97b - Total Current Liabilities 1.66b) / Total Assets 11.7b
B: 0.03 (Retained Earnings 304.5m / Total Assets 11.7b)
C: 0.02 (EBIT TTM 232.7m / Avg Total Assets 9.59b)
D: 1.17 (Book Value of Equity 6.32b / Total Liabilities 5.40b)
Altman-Z'' = 2.77 = A

Beneish M -2.43

DSRI: 1.11 (Receivables 1.06b/855.9m, Revenue 3.41b/3.06b)
GMI: 1.05 (GM 79.56% / 75.55%)
AQI: 1.64 (AQ_t 0.58 / AQ_t-1 0.35)
SGI: 1.11 (Revenue 3.41b / 3.06b)
TATA: -0.07 (NI 73.0m - CFO 857.1m) / TA 11.7b)
Beneish M = -2.43 (Cap -4..+1) = BBB

What is the price of BMRN shares?

As of August 17, 2026, the stock is trading at USD 67.36 with a total of 1,389,860 shares traded. Over the past week, the price has changed by +5.56%, over one month by +12.27%, over three months by +35.62% and over the past year by +17.27%.

Current recommended Stop Loss: 64.80 (which is 3.8% or 1.2 ATR below the current price).

Is BMRN a buy, sell or hold?

Biomarin Pharmaceutical has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy BMRN.

StrongBuy: 16
Buy: 7
Hold: 6
Sell: 0
StrongSell: 0

What are the forecasts/targets for the BMRN price?

Analysts Target Price	90.3	34.1%

Biomarin Pharmaceutical (BMRN) - Fundamental Data Overview as of 14 August 2026

Market Cap USD = 13.6b (13.6b USD * 1.0 USD.USD)
P/E Trailing = 189.8378
P/E Forward = 14.0056
P/S = 3.952
P/B = 2.1104
P/EG = 0.8573
Revenue TTM = 3.41b USD
EBIT TTM = 232.7m USD
EBITDA TTM = 385.7m USD
Long Term Debt = 3.53b USD (from longTermDebt, last quarter)
Short Term Debt = 674.3m USD (from shortTermDebt, last quarter)
Debt = 4.22b USD (from shortLongTermDebtTotal, last quarter) + Leases 16.1m
Net Debt = 3.34b USD (calculated: Debt 4.22b - CCE 874.0m)
Enterprise Value = 16.9b USD (13.6b + Debt 4.22b - CCE 874.0m)
Interest Coverage Ratio = 2.78 (Ebit TTM 232.7m / Interest Expense TTM 83.6m)
EV/FCF = 23.12x (Enterprise Value 16.9b / FCF TTM 732.9m)
FCF Yield = 4.33% (FCF TTM 732.9m / Enterprise Value 16.9b)
FCF Margin = 21.51% (FCF TTM 732.9m / Revenue TTM 3.41b)
Net Margin = 2.14% (Net Income TTM 73.0m / Revenue TTM 3.41b)
Gross Margin = 75.55% ((Revenue TTM 3.41b - Cost of Revenue TTM 833.0m) / Revenue TTM)
Gross Margin QoQ = 79.51% (prev 74.55%)
Tobins Q-Ratio = 1.45 (Enterprise Value 16.9b / Total Assets 11.7b)
Interest Expense / Debt = 1.98% (Interest Expense 83.6m / Debt 4.22b)
Taxrate = 27.08% (16.6m / 61.4m)
NOPAT = 169.7m (EBIT 232.7m * (1 - 27.08%))
Current Ratio = 2.39 (Total Current Assets 3.97b / Total Current Liabilities 1.66b)
Debt / Equity = 0.67 (Debt 4.22b / totalStockholderEquity, last quarter 6.32b)
Debt / EBITDA = 8.67 (Net Debt 3.34b / EBITDA 385.7m)
Debt / FCF = 4.56 (Net Debt 3.34b / FCF TTM 732.9m)
Total Stockholder Equity = 6.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.76% (Net Income 73.0m / Total Assets 11.7b)
RoE = 1.18% (Net Income TTM 73.0m / Total Stockholder Equity 6.17b)
RoCE = 2.40% (EBIT 232.7m / Capital Employed (Equity 6.17b + L.T.Debt 3.53b))
RoIC = 1.61% (NOPAT 169.7m / Invested Capital 10.6b)
WACC = 5.72% (E(13.6b)/V(17.8b) * Re(7.05%) + D(4.22b)/V(17.8b) * Rd(1.98%) * (1-Tc(0.27)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -60.23 | Cagr: -1.15%
[DCF] Terminal Value 76.20% ; FCFF base≈716.3m ; Y1≈755.0m ; Y5≈881.3m
[DCF] Fair Price = 52.83 (EV 13.6b - Net Debt 3.34b = Equity 10.2b / Shares 193.6m; r=8.35% [WACC [floored]]; 5y FCF grow 5.99% → 2.50% )
EPS Correlation: 63.57 | EPS CAGR: 23.72% | SUE: 0.40 | # QB: 0
Revenue Correlation: 99.11 | Revenue CAGR: 15.02% | SUE: 2.45 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.40 | Chg30d=-6.37% | Revisions=+25% | Analysts=14
EPS current Year (2026-12-31): EPS=5.03 | Chg30d=+1.87% | Revisions=+0% | GrowthEPS=+59.7% | GrowthRev=+21.3%
EPS next Year (2027-12-31): EPS=6.63 | Chg30d=+2.68% | Revisions=-25% | GrowthEPS=+31.7% | GrowthRev=+14.0%
[Analyst] Revisions Ratio: +0% (up=2, down=2)